Inventia Healthcare Limited — Glimepiride Exporter Profile
Indian Pharmaceutical Exporter · #4 for Glimepiride · $3.0M export value · DGFT Verified
Inventia Healthcare Limited is the #4 Indian exporter of Glimepiride with $3.0M in export value and 108 verified shipments. Inventia Healthcare Limited holds a 3.9% market share in Glimepiride exports across 6 countries. The company exports 11 pharmaceutical products worth $36.5M across 6 therapeutic categories.
Inventia Healthcare Limited — Glimepiride Export Profile: Buyers & Destinations

Where Does Inventia Healthcare Limited Export Glimepiride?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PHILIPPINES | $760.5K | 22 | 28.1% |
| MALAYSIA | $626.5K | 20 | 23.1% |
| VIETNAM DEMOCRATIC REP. OF | $434.4K | 13 | 16.0% |
| NIGERIA | $364.1K | 23 | 13.4% |
| VIETNAM | $244.0K | 5 | 9.0% |
| GAUTEMALA | $212.4K | 17 | 7.8% |
| VIETNAM, DEMOCRATIC REP. OF | $56.7K | 4 | 2.1% |
| UZBEKISTAN | $10.5K | 4 | 0.4% |
Inventia Healthcare Limited exports Glimepiride to 8 countries. The largest destination is PHILIPPINES accounting for 28.1% of Inventia Healthcare Limited's Glimepiride shipments, followed by MALAYSIA (23.1%) and VIETNAM DEMOCRATIC REP. OF (16.0%). These destinations reflect Inventia Healthcare Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Glimepiride from Inventia Healthcare Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| I.E. MEDICA INC. | PHILIPPINES | $555.4K | 15 |
| MAXXCARE COMPANY LIMITED | VIETNAM DEMOCRATIC REP. OF | $434.4K | 13 |
| HEALOL PHARMACEUTICALS SDN. BHD., | MALAYSIA | $375.5K | 12 |
| MAXXCARE COMPANY LIMITED. | VIETNAM, DEMOCRATIC REP. OF | $297.2K | 8 |
| MAY AND BAKER NIGERIA PLC | NIGERIA | $167.5K | 7 |
| HEALOL PHARMACEUTICALS SDN BHD | MALAYSIA | $156.3K | 5 |
| NOVOSWISS PHARMACEUTICALS, S.A | GAUTEMALA | $155.0K | 8 |
| I E MEDICA INC | PHILIPPINES | $150.0K | 3 |
| TO ZENITH BANK PLC | NIGERIA | $120.3K | 4 |
| TO THE ORDER OF, | NIGERIA | $44.0K | 3 |
Inventia Healthcare Limited supplies Glimepiride to 22 buyers globally. The largest buyer is I.E. MEDICA INC. (PHILIPPINES), followed by MAXXCARE COMPANY LIMITED (VIETNAM DEMOCRATIC REP. OF) and HEALOL PHARMACEUTICALS SDN. BHD., (MALAYSIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Glimepiride Export Value and How Much Does Inventia Healthcare Limited Contribute?
India exported $23.4M worth of Glimepiride through 3,159 shipments from 242 suppliers to 94 countries, serving 535 buyers globally. Inventia Healthcare Limited contributes $3.0M to this total, accounting for 3.9% of India's Glimepiride exports. Inventia Healthcare Limited ships Glimepiride to 8 countries through 22 buyers.
What Is the Average Shipment Value for Inventia Healthcare Limited's Glimepiride Exports?
Inventia Healthcare Limited's average Glimepiride shipment value is $27.6K per consignment, based on 108 shipments totaling $3.0M. The largest destination is PHILIPPINES (28.1% of Inventia Healthcare Limited's Glimepiride exports).
How Does Inventia Healthcare Limited Compare to Other Indian Glimepiride Exporters?
Inventia Healthcare Limited ranks #4 among 242 Indian Glimepiride exporters with a 3.9% market share. The top 3 exporters are MICRO LABS LIMITED ($5.3M), IPCA LABORATORIES LIMITED ($3.6M), INVENTIA HEALTHCARE LIMITED ($3.0M). Inventia Healthcare Limited processed 108 shipments to 6 destination countries.
What Glimepiride Formulations Does Inventia Healthcare Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN H | $200.0K | 4 |
| PERGLIM M -2 (EACH TABLET CONTAIN: GLIMEPIRIDE USP 2 MG & METFORMIN HCL BP 500MG)NOS | $150.0K | 3 |
| PROGLUTROL G2 (GLIMEPIRIDE 2 MG AND METFORMIN HYDROCHLORIDE 500MG SUSTAINED RELEASE TABLETS) (MAL 12020010A) | $126.9K | 4 |
| PROGLUTROL G2 (GLIMEPIRIDE 2 MG AND METF | $125.8K | 4 |
| PERGLIM M -1 (EACH TABLET CONTAIN: GLIMEPIRIDE USP 1 MG & METFORMIN HCL BP 500MG) AS PER INVNOS | $114.8K | 3 |
| PERGLIM M-2 (EACH TABLET CONTAIN: GLIMEPIRIDE USP 2 MG & METFORMIN HCl BP 500 MG) | $97.8K | 2 |
| CO-MEPIRYL FORTE-(GLIMEPIRIDE 2MG AND ME | $86.9K | 2 |
| PERGLIM M -1 (EACH TABLET CONTAIN: GLIMEPIRIDE USP 1 MG & METFORMIN HCL BP 500 MG) AS PER INVNOS | $69.1K | 3 |
| LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN HYDROCHLORIDE SUSTAINED RELEASE 500MG TABLETS)(ACT. QTY: 32700 X 3X10)NOS | $52.9K | 3 |
| LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN HYDROCHLORIDE SUSTAINED RELEASE 500MG TABLETS) (ACT.QTY. 32373 CRTNS X 3X10) | $52.4K | 3 |
Inventia Healthcare Limited exports 80 distinct Glimepiride formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN H with 4 shipments worth $200.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Inventia Healthcare Limited Compare to Nearest Glimepiride Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | MICRO LABS LIMITED | $5.3M | 439 | 18 | $12.1K |
| 3 | IPCA LABORATORIES LIMITED | $3.6M | 90 | 3 | $40.0K |
| 4 | INVENTIA HEALTHCARE LIMITED ★ | $3.0M | 108 | 6 | $27.6K |
| 5 | MEDREICH LIMITED | $2.1M | 42 | 1 | $50.0K |
| 1 | INDOCO REMEDIES LIMITED | $2.0M | 41 | 2 | $50.0K |
Inventia Healthcare Limited ranks #4 among 242 Indian Glimepiride exporters. Average shipment value of $27.6K compared to the market average of $96.6K. The closest competitors by value are MICRO LABS LIMITED and IPCA LABORATORIES LIMITED.
Which Indian Ports Ship Glimepiride Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 350 | 11.1% |
| NHAVA SHEVA SEA (INNSA1) | 268 | 8.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 241 | 7.6% |
| DELHI AIR CARGO ACC (INDEL4) | 228 | 7.2% |
| DELHI AIR | 226 | 7.2% |
| JNPT/ NHAVA SHEVA SEA | 172 | 5.4% |
| BANGALORE ACC (INBLR4) | 148 | 4.7% |
| BANGALORE AIR | 110 | 3.5% |
What Other Diabetes & Endocrine Products Does Inventia Healthcare Limited Export?
Inventia Healthcare Limited also exports these diabetes & endocrine products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Inventia Healthcare Limited's Glimepiride Exports
Inventia Healthcare's extensive export operations are currently navigating a complex geopolitical landscape that presents both challenges and opportunities. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These logistical challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in supply chain management to mitigate potential delays and cost escalations. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced additional complexities for Indian pharmaceutical exporters. The imposition of tariffs on a broad range of imports, including pharmaceuticals, has raised concerns about cost competitiveness and market access. Companies like Inventia must navigate these policy shifts by exploring alternative markets and enhancing operational efficiencies to maintain their competitive edge. (apnews.com)
Conversely, the European Union's stringent regulatory frameworks, such as the Falsified Medicines Directive, necessitate rigorous compliance measures. While these regulations impose additional operational requirements, they also present an opportunity for companies with robust quality systems to differentiate themselves. Inventia's adherence to international quality standards positions it favorably to meet these regulatory demands and strengthen its presence in the European market.
Inventia Healthcare Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency intensifying their focus on manufacturing practices and product quality. For Indian exporters, this translates into the necessity for stringent compliance with Good Manufacturing Practices (GMP) and other regulatory standards.
Inventia Healthcare's manufacturing facility in Ambernath and its research and development center in Thane are accredited by the U.S. FDA, U.K. MHRA, and other stringent regulatory authorities. This compliance underscores the company's commitment to maintaining high-quality standards, facilitating access to both emerging and regulated markets. (platinumequity.com)
However, the broader Indian pharmaceutical sector faces challenges related to quality assurance, with instances of regulatory non-compliance affecting the industry's reputation. To mitigate these risks, companies like Inventia must continually invest in quality control systems, employee training, and process improvements to ensure sustained compliance and market trust.
About Inventia Healthcare Limited
Inventia Healthcare Limited exports 11 products worth $36.5M. Beyond Glimepiride, top products include Metformin, Telmisartan, Dapagliflozin, Gliclazide, Lansoprazole. View the complete Inventia Healthcare Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Glimepiride — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Glimepiride shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Inventia Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 108 individual customs records matching Inventia Healthcare Limited exporting Glimepiride, covering 80 formulations to 8 countries via 22 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 94+ countries, 535+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Glimepiride Export Data from Inventia Healthcare Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Inventia Healthcare Limited's Glimepiride exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Inventia Healthcare Limited
Full Company Profile →
11 products · $36.5M total trade · 6 categories
Glimepiride Stats
Company Overview
Top Products by Inventia Healthcare Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Inventia Healthcare Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Glimepiride. For current shipment-level data, contact TransData Nexus.